Rocklatan approval leads 2019 glaucoma news
Click Here to Manage Email Alerts
In March, the FDA approved Aerie Pharmaceuticals’ netarsudil and latanoprost compound for the treatment of glaucoma and ocular hypertension. The news was the most-read glaucoma article on Healio/OSN in 2019.
Here are the top five glaucoma stories of the past year:
FDA approves Rocklatan for open-angle glaucoma, ocular hypertension
A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP. Read more.
FDA accepts application for Bimatoprost Sustained-Release
Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks. Read more.
Allergan recalls certain lots of Xen 45
Allergan voluntarily recalled certain lots of the Xen 45 glaucoma drainage device after a small number of units in an unreleased lot of the product were observed to have trace amounts of polishing compounds. Read more.
Bimatoprost sustained-release implant reduces IOP in phase 3 study
The majority of patients with open-angle glaucoma or ocular hypertension in the 528-subject trial remained treatment-free for at least 1 year after the last implant was inserted. Read more.
VIDEO: Switching to ab externo approach leads to better outcomes with Xen gel stent
At the Kiawah Eye meeting here, Nathan Radcliffe, MD, discusses how and why switching from an ab interno to ab externo technique with implantation of the Xen gel stent MIGS device (Allergan) has improved his results in treating patients with glaucoma. Watch video.